Several vaccine-based strategies, including carcinoembryonic antigen RNA-pulsed DCs and immunogenic peptides plus gemcitabine, have been developed for CCA treatment, singly or in combination (111). The gene discussed is CEACAM5; the disease is cholangiocarcinoma.